Is Cardinal Health (CAH) overvalued or fairly valued?

MarketChacha shows Cardinal Health's valuation in context — a trailing P/E of about 38.2, a forward P/E of about 16.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Cardinal Health's reported profit turn into cash?

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (3.18×) from reported figures — education, not a rating.

What is Cardinal Health's revenue?

Cardinal Health reported revenue of $254.2B for FY2026, with net profit of $1.7B, per official filings.

What is the share price of Cardinal Health (CAH)?

Cardinal Health last traded at $234.98 (-0.3% on the day), as of 8/18/2026 — a delayed quote shown for education, not investment advice.

Cardinal Health

CAH · NYSE · Healthcare · United States

Snapshot

TickerCAH

ExchangeNYSE

SectorHealthcare

IndustryMedical Distribution

CountryUnited States

CEOMs. Deborah L. Weitzman

Employees58,788

HeadquartersDublin, United States

Websitewww.cardinalhealth.com

Filings tracked19

About Cardinal Health

Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company offers customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The company also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; pharmacy management services to hospitals; operates pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compression, incontinence, nutritional delivery, and wound care products; single-use surgical drapes, gowns, and apparel products; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. Further, the company distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile and non-sterile procedure kits. Additionally, it manufactures, prepares, and delivers radiopharmaceuticals; and optimizes direct shipments through integrated technology solutions. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.

Who owns it

Insiders0.4%
Institutions90.9%
Public & other8.7%

1,980 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.11.39%
Vanguard Capital Management LLC6.58%
Wellington Management Group, LLP6.39%
Vanguard Portfolio Management LLC5.90%
State Street Corporation5.15%
Geode Capital Management, LLC2.78%
Invesco Ltd.2.04%
Morgan Stanley1.99%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion3.18×

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend0.2% → 0.7%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 7% · PAT 73%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $68.2B · EPS 3.12

Est. earnings growth +18.6%

Next fiscal year

Rev $281.8B · EPS 14.02

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2026)

$254.2B

Net margin

0.7%

Revenue CAGR (3y)

+7.4%

Profit CAGR (3y)

+73.2%

EPS (FY2026)

7.23

Net profit (FY2026)

$1.7B

Ask MarketChacha about CAH

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	$254.2B	$1.7B	7.23	0.7%
FY2025	$222.6B	$1.6B	6.45	0.7%
FY2024	$226.8B	$852.0M	3.45	0.4%
FY2023	$205.0B	$330.0M	1.26	0.2%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2025Q4	$65.6B	$467.0M	—	0.7%
2025Q3	$64.0B	$450.0M	1.88	0.7%
2025Q1	$54.9B	$506.0M	—	0.9%
2024Q4	$55.3B	$400.0M	—	0.7%
2024Q3	$52.3B	$416.0M	1.70	0.8%
2024Q1	$54.9B	$261.0M	1.07	0.5%
2023Q4	$57.4B	$368.0M	1.50	0.6%
2023Q3	$54.6B	$-12.0M	-0.05	-0.0%
2023Q1	$50.5B	$365.0M	1.41	0.7%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Material agreement, Termination of agreement, Material financial obligation, Exhibits
SEC8/11/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC8/11/2026material
8-K — Executive/director change
SEC8/5/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC4/30/2026material
10-Q filing
SEC4/30/2026
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC3/23/2026material
8-K — Executive/director change
SEC3/5/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC2/5/2026material
10-Q filing
SEC2/5/2026
8-K — Reg FD disclosure, Exhibits
SEC1/13/2026material

2025

8-K — Shareholder vote results
SEC11/6/2025material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC10/30/2025material
10-Q filing
SEC10/30/2025
8-K — Material agreement, Exhibits
SEC10/10/2025material
8-K — Material agreement, Exhibits
SEC10/3/2025material
8-K — Material agreement, Material financial obligation, Exhibits
SEC8/27/2025material
8-K — Other events, Exhibits
SEC8/14/2025material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC8/12/2025material
10-K filing
SEC8/12/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.